• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Celldex Therapeutics (CLDX) Valuation After Launching Second Global Phase 3 Program for Barzolvolimab

    Simply Wall St·12/09/2025 19:13:05
    语音播报

    Celldex Therapeutics (CLDX) just kicked off a global Phase 3 trial for barzolvolimab in cold urticaria and symptomatic dermographism, building directly on strong Phase 2 data in patients who failed standard antihistamines.

    See our latest analysis for Celldex Therapeutics.

    The Phase 3 launch comes as Celldex’s momentum picks up, with a 30 day share price return of about 30 percent and a solid 1 year total shareholder return, even though the 3 year total shareholder return is still negative.

    If this kind of late stage biotech story interests you, it might be worth exploring other potential opportunities across healthcare stocks for more ideas in the healthcare space.

    The stock has rallied sharply on the back of barzolvolimab’s progress and now trades at a steep discount to analyst targets. This raises a key question for investors: is this a buying opportunity, or is future growth already priced in?

    Price-to-Book of 3.3x: Is it justified?

    On a price to book basis, Celldex trades at 3.3 times, which sits above the broader US biotech sector but below its closest peers.

    The price to book ratio compares the company’s market value to its net assets and is often used for early stage or loss making biotechs where earnings are not yet meaningful. For Celldex, this lens highlights how much investors are willing to pay today for a pipeline and platform that are not yet generating substantial revenue or profits.

    Celldex screens as expensive versus the wider US biotech industry, with its 3.3 times price to book multiple topping the sector average of 2.7 times. This suggests the market is assigning a premium to its barzolvolimab opportunity set. Yet that same multiple looks more restrained when stacked against a 4.4 times peer average. This implies that while sentiment has improved, investors are still pricing Celldex at a relative discount to some similarly positioned development stage names.

    See what the numbers say about this price — find out in our valuation breakdown.

    Result: Price-to-book of 3.3x (ABOUT RIGHT)

    However, investors should still weigh clinical trial setbacks or prolonged cash burn, both of which could quickly undermine sentiment and put pressure on the share price.

    Find out about the key risks to this Celldex Therapeutics narrative.

    Build Your Own Celldex Therapeutics Narrative

    If you see things differently or would rather dive into the numbers yourself, you can build a personalized view in just minutes: Do it your way.

    A great starting point for your Celldex Therapeutics research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.

    Looking for more investment ideas?

    Before you move on, lock in your next moves with targeted stock ideas on Simply Wall Street, so you are not left reacting after the market moves.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.